AI drug discovery company Oxford Drug Design has successfully completed in vivo validation of a novel therapeutic approach targeting multiple tumour types. In studies using a genetically engineered mouse model that replicates the earliest mutational events in colorectal cancer, Oxford Drug Design’s lead compound demonstrated statistically significant anti-tumour… Read More
Oxford Drug Design has been awarded £1 ($1.2) million in funding to progress its uUTI (uncomplicated urinary tract infection) antibacterial programme from PACE (Pathways to Antimicrobial Clinical Efficacy). In the UK, there were over 1.8 million hospital admissions involving UTIs between 2018-19 and 2022-23, with the condition being responsible for… Read More
Results of an in vivo mouse colorectal cancer model study have shown a 60% life extension for Oxford Drug Design’s first-in-class approach against multiple tumours. The results follow previous in vivo validation of the therapeutic candidates and have led to… Read More
In vivo testing has validated Oxford Drug Design’s potential first-in-class approach against multiple tumours, designed using its AI platform. The results of a 28-day mouse trial showed clear efficacy as well as dose response. The company’s approach is based on a novel target, leucyl-tRNA… Read More
